Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
BCRX

Price
6.75
Stock movement up
+0.03 (0.45%)
Company name
BioCryst Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
1.42B
Ent value
2.17B
Price/Sales
2.37
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
21.60
PEG
-
EPS growth
-14.52%
1 year return (CAGR)
-11.30%
3 year return (CAGR)
-
5 year return (CAGR)
-
10 year return (CAGR)
-
Last updated: 2026-01-22

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

BCRX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF28.63
Price to FCF30.05
Price to EBITDA16.96
EV to EBITDA25.90

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.37
Price to Book-
EV to Sales3.62

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count210.74M
EPS (TTM)-0.04
FCF per share (TTM)0.22

Income statement

Loading...
Income statement data
Revenue (TTM)599.82M
Gross profit (TTM)583.80M
Operating income (TTM)76.10M
Net income (TTM)-8.78M
EPS (TTM)-0.04
EPS (1y forward)0.31

Margins

Loading...
Margins data
Gross margin (TTM)97.33%
Operating margin (TTM)12.69%
Profit margin (TTM)-1.46%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash84.08M
Net receivables91.33M
Total current assets355.68M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment19.24M
Total assets446.42M
Accounts payable5.57M
Short/Current long term debt683.11M
Total current liabilities190.24M
Total liabilities834.31M
Shareholder's equity-387.89M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)49.68M
Capital expenditures (TTM)2.34M
Free cash flow (TTM)47.34M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-1.97%
Return on Invested Capital2.52%
Cash Return on Invested Capital-13.59%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.69
Daily high6.87
Daily low6.63
Daily Volume6.67M
All-time high33.13
1y analyst estimate20.60
Beta0.91
EPS (TTM)-0.04
Dividend per share0.00
Ex-div date-
Next earnings date25 Feb 2026

Downside potential

Loading...
Downside potential data
BCRXS&P500
Current price drop from All-time high-79.62%-0.89%
Highest price drop-80.65%-19.00%
Date of highest drop10 Apr 20258 Apr 2025
Avg drop from high-75.65%-2.49%
Avg time to new high-6 days
Max time to new high322 days89 days
COMPANY DETAILS
BCRX (BioCryst Pharmaceuticals Inc) company logo
Marketcap
1.42B
Marketcap category
Small-cap
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Employees
580
Investor relations
SEC filings
CEO
Jon P. Stonehouse
Country
USA
City
Durham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...